Nivo/Ipi Combo Now ‘Standard of Care’ in Mesothelioma
The immunotherapy combination of nivolumab (Opdivo) and ipilimumab (Yervoy) offers a durable, long-term survival benefit over chemotherapy for patients with
Read more
Study finds drug beneficial for shrinking mesothelioma tumors
A drug that is designed to boost the immune system against mesothelioma, when combined with immunotherapy, was found to be
Read more